Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. [6]

Diabetes Care

Volumn 30, Issue 4, 2007, Pages

  Jellinger, Paul S ^a,d   Lebovitz, Harold E ^b   Davidson, Jaime A ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MACE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; INSULIN DERIVATIVE; INSULIN GLARGINE; METFORMIN; PRAMLINTIDE;

ALGORITHM; CONSENSUS; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LETTER; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ALGORITHMS; DIABETES MELLITUS, TYPE 2; EUROPE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 34147143529     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2373     Document Type: Letter

References (10)

1. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972, 2006
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721, 2006
3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
4. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413-420, 2004
5. Lebovitz HE: Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. Endocr Pract 12:142-147, 2006
6. 1c. Diabetes Care 26:881-885, 2003
7. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562-568, 1999
8. Parikh H, Groop L: Candidate genes for type 2 diabetes. Rev Endocr Metab Disord 5:151-176, 2004
9. Esposito K, Giugliano D, Nappo F, Marfella R, the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003